Company Forte Biosciences, Inc.

Equities

FBRX

US34962G1094

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 21:30:01 25/06/2024 BST			5-day change	1st Jan Change
0.46 ^USD	-6.12%		-10.92%	-44.02%

05-30	Brookline Capital Initiates Forte Biosciences at Buy Rating With $4 Price Target	MT
05-13	Forte Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Companyâs FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Companyâs subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.

Number of employees: 11

Managers	Title	Age	Since
Paul Wagner CEO	Chief Executive Officer	53	31/12/16
Anthony Riley DFI	Director of Finance/CFO	57	29/02/20
Christopher Roenfeldt COO	Chief Operating Officer	-	30/09/20
Steven J. Ruhl CTO	Chief Tech/Sci/R&D Officer	-	30/06/21

Members of the board	Title	Age	Since
David Gryska BRD	Director/Board Member	68	09/01/23
Steven Kornfeld BRD	Director/Board Member	56	31/05/20
Stephen Doberstein BRD	Director/Board Member	65	11/05/22
Barbara Finck BRD	Director/Board Member	77	15/03/22
Paul Wagner CEO	Chief Executive Officer	53	31/12/16
Donald Williams BRD	Director/Board Member	65	31/05/20
Scott Brun BRD	Director/Board Member	56	09/11/22
Lawrence Eichenfield BRD	Director/Board Member	66	31/05/20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	36,442,380	29,201,216 ( 80.13 %)	0	80.13 %

Name	Equities	%	Valuation
Tybourne Capital Management (HK) Ltd. 9.946 %	3,624,548	9.946 %	2 M $
Perceptive Advisors LLC 8.960 %	3,265,359	8.960 %	2 M $
BVF, Inc. 8.183 %	2,982,105	8.183 %	2 M $
Cable Car Capital LLC 5.576 %	2,031,987	5.576 %	1 M $
Paul Wagner 5.157 %	1,879,174	5.157 %	1 M $
Fred Alger Management LLC (13f Subfiler) 5.046 %	1,838,965	5.046 %	1 M $
Farallon Capital Management LLC 4.968 %	1,810,455	4.968 %	1 M $
BML Capital Management LLC 4.834 %	1,761,702	4.834 %	1 M $
ATG Capital Management LLC 4.012 %	1,462,000	4.012 %	868 428 $
Camac Partners LLC 3.505 %	1,277,176	3.505 %	758 643 $

Forte Biosciences, Inc.

3060 Pegasus Park Drive Building 6

75247, Dallas

http://www.fortebiorx.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.46 USD

Average target price

3.375 USD

Spread / Average Target

+633.70%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
FORTE BIOSCIENCES, INC.	-44.02%	17.86M
VERTEX PHARMACEUTICALS INCORPORATED	+16.45%	123B
REGENERON PHARMACEUTICALS, INC.	+21.96%	115B
ARGENX SE	+23.73%	25.85B
BIONTECH SE	-20.05%	20.9B
BEIGENE, LTD.	-16.28%	16.77B
GENMAB A/S	-16.52%	16.52B
WUXI APPTEC CO., LTD.	-44.35%	15.56B
SAREPTA THERAPEUTICS, INC.	+63.91%	15.49B
NEUROCRINE BIOSCIENCES, INC.	+2.52%	13.45B

Bio Therapeutic Drugs